腦下垂體腫瘤內分泌病變新進展

10.6666/ClinMed.202105_87(5).0054

郝立智；張雅椅；蔡宗憲；陳映佐；洪培恩；黃孟華；簡崇仁；葉美成；楊純宜

腦下垂體腺瘤（pituitary adenoma） ； 促乳素瘤（prolactinoma） ； 似胰島素生長因子-1（insulin-like growth factor-1, IGF-1） ； 體抑素衍生物（somatostatin analogs） ； 經蝶竇垂體瘤切除術（transsphenoidal adenomectomy）

臨床醫學月刊

87卷5期（2021 / 05 / 28）

321 - 335

繁體中文

腦下垂體腺瘤約佔顱內腫瘤的15%，若要處理這些良性腫瘤，需要診斷出特定的鞍腔內疾病，並需要對局部腫塊和周圍內分泌病變進行全面的多專科治療。由於腫瘤可以產生不同的激素，因此其預後和治療方法差異很大。腦下垂體腺瘤的綜合處置包括經蝶竇垂體瘤手術切除術、放射治療和藥物治療，每種方法都有各自針對不同腺瘤類型的優點和缺點，可能需要各別系列的或合併的治療方法。為了獲得足夠的良好生化結果，需要進行手術切除和輔助治療。

1. Agustsson, TT,Baldvinsdottir, T,Jonasson, JG(2015).The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study.Eur J Endocrinol,173,655-664.
2. Ayuk, J,Clayton, RN,Holder, G(2004).Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.J Clin Endocrinol Metab,89,1613-1617.
3. Azzalin, A,Appin, CL,Schniederjan, MJ(2016).Comprehensive evaluation of thyrotropinomas: single-center 20-year experience.Pituitary,19,183-193.
4. Bi, WL,Larsen, AG,Dunn, IF(2018).Genomic alterations in sporadic pituitary tumors.Curr Neurol Neurosci Rep,18,4.
5. Buchfelder, M,Schlaffer, SM(2017).The surgical treatment of acromegaly.Pituitary,20,76-83.
6. Casanueva, FF,Barkan, AL,Buchfelder, M(2017).Criteria for the definition of Pituitary Tumor Centers of Excellence(PTCOE): a Pituitary Society statement.Pituitary,20,489-498.
7. Chen, L,White, WL,Spetzler, RF(2011).A prospective study of nonfunctioning pituitary adenomas: presentation, management, and clinical outcome.J Neurooncol,102,129-138.
8. Colao, A,Grasso, LFS,Giustina, A(2019).Acromegaly.Nat Rev Dis Primers,5,20.
9. Correa, R,Salpea, P,Stratakis, CA(2015).Carney complex: an update.Eur J Endocrinol,173,M85-M97.
10. Cuevas-Ramos, D,Carmichael, JD,Cooper, O(2015).A structural and functional acromegaly classification.J Clin Endocrinol Metab,100,122-131.
11. Dal, J,Feldt-Rasmussen, U,Andersen, M(2016).Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study.Eur J Endocrinol,175,181-190.
12. Delgrange, E,Trouillas, J,Maiter, D(1997).Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study.J Clin Endocrinol Metab,82,2102-2107.
13. Ding, D,Mehta, GU,Patibandla, MR(2019).Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study.Neurosurgery,84,717-725.
14. Drummond, J,Roncaroli, F,Grossman, AB(2019).Clinical and pathological aspects of silent pituitary adenomas.J Clin Endocrinol Metab,104,2473-2489.
15. Famini, P,Maya, MM,Melmed, S(2011).Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients.J Clin Endocrinol Metab,96,1633-1641.
16. Feelders, RA,Newell-Price, J,Pivonello, R(2019).Advances in the medical treatment of Cushing´s syndrome.Lancet Diabetes Endocrinol,7,300-312.
17. Fountas, A,Lavrentaki, A,Subramanian, A(2018).Recurrence in silent corticotroph adenomas after primary treatment: a systematic review and meta-analysis.J Clin Endocrinol Metab
18. Freda, PU,Beckers, AM,Katznelson, L(2011).Pituitary incidentaloma: an Endocrine Society clinical practice guideline.J Clin Endocrinol Metab,96,894-904.
19. Giustina, A,Mazziotti, G,Cannavò, S(2017).High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study.J Clin Endocrinol Metab,102,2454-2464.
20. Goldenberg, N,Racine, MS,Thomas, P(2008).Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant.J Clin Endocrinol Metab,93,2953-2956.
21. Huang, W,Molitch, ME(2018).Management of nonfunctioning pituitary adenomas(NFAs): observation.Pituitary,21,162-167.
22. Ioachimescu, AG,Fleseriu, M,Hoffman, AR(2019).Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.Eur J Endocrinol,180,31-40.
23. Lacroix, A,Gu, F,Gallardo, W(2018).Efficacy and safety of once-monthly pasireotide in Cushing´s disease: a 12 month clinical trial.Lancet Diabetes Endocrinol,6,17-26.
24. Lee, CC,Vance, ML,Xu, Z(2014).Stereotactic radiosurgery for acromegaly.J Clin Endocrinol Metab,99,1273-1281.
25. Liu, W,Zahr, RS,McCartney, S(2018).Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study.Pituitary,21,454-462.
26. Melmed, S(2020).Pituitary-Tumor Endocrinopathies.N Engl J Med,382,937-950.
27. Molitch, ME(2017).Diagnosis and treatment of pituitary adenomas: a review.JAMA,317,516-524.
28. Nieman, LK(2018).Diagnosis of Cushing´s syndrome in the modern era.Endocrinol Metab Clin North Am,47,259-273.
29. Ragnarsson, O,Olsson, DS,Chantzichristos, D(2019).The incidence of Cushing´s disease: a nationwide Swedish study.Pituitary,22,179-186.
30. Ritvonen, E,Löyttyniemi, E,Jaatinen, P(2016).Mortality in acromegaly: a 20-year follow-up study.Endocr Relat Cancer,23,469-480.
31. Schmid, HA,Brue, T,Colao, A(2016).Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.Endocrine,53,210-219.
32. Terzolo, M,Reimondo, G,Berchialla, P(2017).Acromegaly is associated with increased cancer risk: a survey in Italy.Endocr Relat Cancer,24,495-504.
33. 林仁德(2013)。功能性垂體腺瘤之內科治療。內科學誌，4，265-270。
34. 莊啟政。不到傷口的腦瘤切除手術～經鼻內視鏡腦下垂體腫瘤切除術。長庚醫訊，35(10)，321-324。